Download Transition at Teva: Blockbuster drug Copaxone to lose patent protection in 2014 Brochure

Brochure
More information from http://www.researchandmarkets.com/reports/2878449/
Transition at Teva: Blockbuster drug Copaxone to lose patent protection in
2014
Description:
Introduction
In October 2013, Teva announced that it would be cutting approximately 10% of the workforce in order to
cut costs. Later that month, it announced the departure of its CEO of just 18 months, Jeremy Levin, who was
forced out by Chairman Phillip Frost. This case study looks out how Teva, one of the largest pharmaceuticals
companies in the world, has ended up in this position, & what the future holds
Features and benefits
- This case study looks at Teva's operations and the market in which it operates. It also looks in detail at
Copaxone, Teva's best-selling drug.
- The case study examines the M&A activity Teva has been involved in over recent years, and whether or not
it has been successful.
- Teva's future engines of growth are discussed, as well as 2 outlooks for 2014, depending on generic
competition for Copaxone.
Highlights
In the US, one in every seven prescriptions is filled with a Teva product, and in the UK, this rises to one in
every six prescriptions. The company operates in over 60 countries worldwide and employs approximately
45,000 people. Teva has over 55,000 product variants and 1,000 molecules, and manufactured 64 billion
tablets and capsules in 2013.
Copaxone is one of Teva's best-selling drugs, with global sales of $3.9bn in 2012 and $4.3bn in 2013.
Copaxone accounted for 49% of the specialty drugs segment's sales in 2012, rising to 52% in 2013. However,
Copaxone may face generic competition as early as May 2014.
The New Therapeutic Entities (NTE) program, launched in December 2012, uses existing, known molecules
that can offer improvements for patients by being formulated, delivered or used in a novel way.
Development of NTEs is less time consuming, less risky, and less expensive.
Your key questions answered
- Why is Copaxone losing patent protection and what is Teva doing to alleviate this?
- What is the NTE program?
- What is the outlook for Teva in 2014?
Contents:
OVERVIEW
Catalyst
Summary
TEVA PHARMACEUTICALS IS A LEADER IN GENERIC PHARMACEUTICALS
Teva is a global generics giant
Generic drugs are cheap and effective versions of branded drugs
Teva operates through three segments: generics, specialty, and other
Teva is a global powerhouse in generic medicine
The specialty segment is the second largest, with revenues of $8.4bn in 2013
The other segment accounts for 10% of sales
COPAXONE'S PATENT PROBLEMS AND POOR M&A ACTIVITY HAVE AFFECTED TEVA
Copaxone faces losing its patent in 2014
Teva is losing its patent early
Teva is attempting to move existing Copaxone patients to its new version
A string of questionable acquisitions has severely impacted Teva
NTE DEVELOPMENT AND INTEGRATED GENERIC AND R&D ORGANIZATION ARE PRIMARY ENGINES OF
GROWTH
Teva's NTE program finds advances on existing therapies
The NTE program has several benefits which could propel growth for Teva
Teva is extremely optimistic about its NTE program
Analysts are unenthusiastic about Teva's strategy
Teva has an appetite for "game-changing deals"
TEVA IN TRANSITION
Change at Teva is causing ripples in the stock market
Teva anticipates two outlooks for 2014
The "Generic Copaxone" scenario assumes the launch of at least two generic competitors to Copaxone in
June 2014
The "Exclusive Copaxone" scenario assumes no generic competition to Copaxone in June 2014
Teva is aggressive in its efforts to stave off generic competition
Teva plans to focus on NTE, R&D, and cost reduction
CONCLUSIONS
Teva has attempted to mitigate the loss of Copaxone's patent
APPENDIX
Definitions
Sources
Further Reading
Ask the analyst
About MarketLine
Disclaimer
Ordering:
Order Online - http://www.researchandmarkets.com/reports/2878449/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Transition at Teva: Blockbuster drug Copaxone to lose patent protection in 2014
Web Address:
http://www.researchandmarkets.com/reports/2878449/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Single User:
USD 495
Electronic (PDF) Enterprisewide:
USD 1238
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World